Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase

Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase

Kynurenine-3-monooxygenase (KMO) is an emerging clinical target for treatment of neurodegenerative diseases and acute pancreatitis. Here, the authors report potent inhibitors that bind KMO in an unexpected conformation, offering structural and mechanistic insights for future drug discovery ventures.

Guardado en:
Detalles Bibliográficos
Autores principales: Jonathan P. Hutchinson, Paul Rowland, Mark R. D. Taylor, Erica M. Christodoulou, Carl Haslam, Clare I. Hobbs, Duncan S. Holmes, Paul Homes, John Liddle, Damian J. Mole, Iain Uings, Ann L. Walker, Scott P. Webster, Christopher G. Mowat, Chun-wa Chung
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6a2d1e05cbf54050aa6e26f4834e4b9a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Kynurenine-3-monooxygenase (KMO) is an emerging clinical target for treatment of neurodegenerative diseases and acute pancreatitis. Here, the authors report potent inhibitors that bind KMO in an unexpected conformation, offering structural and mechanistic insights for future drug discovery ventures.

Ejemplares similares